fredgoodwinson wrote: Somewhere between hope and wishful thinking Patience? - I`m the same as it’s the nearest we’re being allowed to get but can`t see anything paternalistic or benevolent in this silence. They just have us a update?
We wait to learn whether TLD-1433 has any advantage over its’ competitors in NMIBC while knowing that in truth what separates Theralase from a host of other moderately promising biotechs is a stated potential to safely treat non-superficial cancers with metal-based photo-sensitisers. With a possibly unique status in being free of legal issues consequent on Sherri`s later work in the US this may - without separate negotiation - in essence mean the derivative Rutherrin.
Rutherrin is well known to TLT and its` Scientists. Its` promise as presented in Dr.Lilge`s excellent AGM lectures back when the Company told us things held out a hope only amplified by later revelation that it could be activated by low dose exogenous x-ray to safely destroy deep-seated tumours. Rember when vester 111 asked in the meeting about rutherrin and lith told him flat out its not needed for the ph3.
Recent news flow has been progressively troubling but the sense of unease began even before the Company dropped one indication rowed back from any timeline for another and announced delays around issues relating to the injection of a drug that they’ve been injecting for years in a setting with clear alternative methods of delivery. Fred, they are treating patinets and issues were resoved. Patinets being treated and study advancing now on Full dose treatments
Despite exhaustive pre-clinical due diligence it is always possible for a compound to present unanticipated challenges and limitations in translation to the Clinic but the Company has much explaining to do. Such information is existentially material and could not be more price sensitive. Lucly ther preclinical due duligance and bore a very succesful PH3 (2B)
They could start by telling us why they have dropped GBM and confirm that GLP has been completed for NSCLC. they are just focused on PH3(2b) and the virus. but going at it stong in the new lab.
It is all the more galling given the disappearance of the timeline to think that RPCCC were seriously considering the use of state of the art technology to activate TLD-1433 in the lungs and that it might have happened by now.